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Abstract
Background: Bacterial peritonitis is serious disease and remains a diagnostic challenge for clinicians. Many studies
have highlighted the potential usefulness of procalcitonin (PCT) for identification of bacterial peritonitis, however,
the overall diagnostic value of PCT remains unclear. Therefore, we performed a meta-analysis to assess the accuracy
of PCT for detection of bacterial peritonitis.
Methods: We performed a systematic searched in MEDLINE, EMBASE, SCOPUS, China Biology Medicine Database
(CBM), China National Knowledge Infrastructure Database (CNKI) and Cochrane databases for trials that evaluated
the diagnostic role of PCT for bacterial peritonitis. Sensitivity, specificity and other measures of accuracy of PCT
were pooled using bivariate random effects models.
Results: Eighteen studies involving 1827 patients were included in the present meta-analysis. The pooled sensitivity
and specificity of serum PCT for the diagnosis bacterial peritonitis were 0.83 (95% CI: 0.76–0.89) and 0.92 (95% CI:
0.87–0.96), respectively. The positive likelihood ratio was 11.06 (95% CI: 6.31–19.38), negative likelihood ratio was
0.18 (95% CI: 0.12–0.27) and diagnostic odds ratio (DOR) was 61.52 (95% CI: 27.58–137.21). The area under the
receiver operating characteristic curve (AUROC) was 0.94. Use of a common PCT cut-off value could improve the
DOR to 75.32 and the AUROC to 0.95. Analysis of the seven studies that measured serum C-reactive protein (CRP)
indicated that PCT was more accurate than CRP for the diagnosis of bacterial peritonitis.
Conclusions: Our results indicate that PCT determination is a relatively sensitive and specific test for the diagnosis
of bacterial peritonitis. However, with regard to methodological limitations and significant heterogeneity, medical
decisions should be based on both clinical findings and PCT test results.
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Background
Bacterial peritonitis is an inflammation of the periton-
eum by micro-organisms such as Gram negative bacilli.
The mortality of peritonitis in the early 1900s was close
to 90%. With the introduction of various antibiotics, the
mortality continued to decrease slowly [1]. However, it is
still a common illness that adversely affects the progno-
sis, and increases costs to health-care systems world-
wide. It frequently occurs in children and adults, and
can endanger life, particularly in patients who have
decompensated cirrhosis or in patients receiving con-
tinuous ambulatory peritoneal dialysis therapy. Previous
studies showed an average peritonitis rate of 1 episode
per 24.5 patient treatment months for continuous am-
bulatory peritoneal dialysis [2]. While the prevalence of
bacterial peritonitis in cirrhotic patients with ascites ad-
mitted to hospital ranges ranging 10% to 30% [3]. It has
been proven that delayed diagnosis of peritonitis was an
important factor for its high mortality, Consequently,
diagnosis of bacterial peritonitis continues to be a major
clinical challenge, and an accurate biomarker for the
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Several potential biomarkers have been proposed in
highly cited studies for their ability to diagnose bac-
terial infections, procalcitonin (PCT), which is a
precursor of calcitonin including 116-aminoacid poly-
peptide has been indicated the “the champion” so far
[4]. It is undetectable (<0.01 ng/ml) in normal condi-
tions, while in cases of infection, it increases rapidly
produced by extrathyroidal cells (e.g. monocytes) [5].
There is a significant body of clinical research indicat-
ing a good diagnostic accuracy for the PCT test for
discrimination between invasive fungal infection and
bacterial infection or noninfectious conditions [4,6].
However, only one systematic review has investigated
the accuracy of PCT for the diagnosis of spontaneous
bacterial peritonitis [7], with limitation of the small
number of trials included. Additionally, several new
studies of PCT have been published and our know-
ledge of PCT is still developing. Therefore, we under-
took the present meta-analysis and systemic review
mainly to quantitatively summarize the current evi-
dence on the value of PCT as a marker of bacterial
peritonitis. Because there is no consensus about the
appropriate PCT cut-off level to predict bacterial peri-
tonitis, and as different PCT thresholds have been
used between studies, we calculated the summary re-
ceiver operating characteristic (ROC) curves approach
to perform this analysis [8].
Methods
Data sources and search strategy
This meta-analysis was performed according to the
meta-analysis of observational studies in epidemiology
reporting guidelines [9]. We performed a literature
search in MEDLINE, EMBASE, SCOPUS, Cochrane da-
tabases, China Biology Medicine Database (CBM), and
China National Knowledge Infrastructure (CNKI) Data-
base (all to April 2014) adhering to PRISMA guidelines
to identify eligible studies. The following search terms
were used: procalcitonin, PCT, peritonitis, ascites, peri-
toneal, abdominal cavity, infection in combination with
biomarker (Figure 1 shows details of the search method
used in this meta-analysis). Published studies were
sought initially without language restrictions. The pa-
tients with any active infection in other organs or sites,
active immune disease, or cancer were excluded. We
also reviewed the reference lists of the original and
review articles in order to identify other potentially rele-
vant trials.
Figure 1 Flow diagram of study identification and inclusion.
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Study selection
Only studies that investigated the diagnostic accuracy
of PCT level to predict peritonitis in humans were
considered for inclusion in this meta-analysis. We in-
cluded prospective and retrospective studies. For the
full-text review and the final analysis, we only in-
cluded articles published in English and Chinese al-
though there was no language restrictions. We
excluded case reports, conference abstracts, review
and letters to journal editors. Three of the authors (S.
K.Y. L.X and P.A.S.) independently evaluated the titles
and abstracts, and excluded all studies that were
clearly not relevant with the inclusion criteria, then
three authors (S.K.Y., P.A.S. and L.X.) assessed the
full-text articles independently. We presented the rea-
sons for study exclusion and progress in Figure 1.
Data extraction and quality assessment
The following data were extracted or recalculated:
year of publication, country of origin, sample size, pa-
tients ages, study design, PCT testing systems, specifi-
city and sensitivity. The data of 2 × 2 tables (true-
positive, false-positive false-negative and true-negative)
were calculated for meta-analysis. These data were ex-
tracted independently by two authors (S.K.Y. and P.A.
S.), and in cases of missing data, we contacted the
corresponding author by e-mails in order to seek the
required information. We used the Quality Assess-
ment of Diagnostic Accuracy Studies (QUADAS) cri-
teria to assess the quality of included studies [10].
When different sensitivity or specificity values were
reported in a study at different cutoffs, the data with
the highest Youden index was used for meta-analysis
[11]. Then the data of 2 × 2 tables were entered into
Stata12.0 by S.K.Y. and the data entry was checked by
X.X.X.
Data synthesis and statistical analysis
The meta-analyses were performed using Stata,version
12.0 (Stata Corp., College Station, TX, USA) [12],
notably with the “midas” and “metandi” commands.
We calculated the pooled sensitivity and specificity,
diagnostic odds ratio (DORs) and the likelihood ratio
et al. based on the bivariate random effect models for
meta-analysis of diagnostic test data [13]. In case
multiple cut-off points for PCT analysis were provided
in a same study, we choose the cut-off giving the
maximum overall accuracy. We also constructed the
respective summary receiver operating characteristic
curves(SROC) and calculated the area under the re-
ceiver operating characteristic curve (AUROC), irre-
spective of different cut-off points used [14].
Heterogeneity was quantitatively assessed using the I2
statistic (I2 value > 50% means a moderate to high
heterogeneity) [15]. Remarkable heterogeneity was ex-
plored further by subgroup analysis. All statistical tests
were two-sided and statistical significance was defined as
P < 0.05. To test for possible publication bias, we con-
structed effective sample size funnel plots versus the log
diagnostic odds ratio and did a regression test of asym-
metry (Deek’s test), with P < 0.05 for the slope coefficient
indicating significant publication bias [16].
Results
Identification of studies
Overall, Our electronic search yielded 385 published
studies, of which 305 studies irrelevant to this review
were excluded after screening titles and abstracts. Hav-
ing reviewed the full text of the remaining 80 articles,
we then excluded another 62 studies: among them, 25
was review article; 7 was case reports; 2 was animal
studies, 7 did not investigate the diagnostic value of
serum PCT level or explore other outcomes; and 15 was
not English or Chinese in the text; and 6 studies was un-
able to reconstruct 2 × 2 tables. Finally, 18 eligibility
studies were included in the analysis [17-34] [Figure 1].
Study characteristics
The main characteristics of included studies were sum-
marized in Table 1.
Nine studies were published in English [17-25], and
nine in Chinese [26-34], representing an international
experience from 5 countries. There were two trials per-
formed by the same research unit [26,29], but the pa-
tients in these two studies were recruited from different
cohorts. Overall, 1827 patients were enrolled. All studies
were conducted in adult patients. 4 of them referred to
peritonitis in peritoneal dialysis patients [17-20], 12 stu-
dies reported spontaneous bacterial peritonitis in cirrhotic
patients [21-23,25-32,34], 1 study were from spontaneous
bacterial peritonitis of chronic severe hepatitis patients
[24], and 1 study was from spontaneous bacterial peri-
tonitis of end stage liver disease patients [33]. Fourteen
studies [21-34] used ascitic polymorphonuclear(PMN)
cells >250/mm3, while four studies [17-20] used ascitic
PMN >50/mm3 as the reference diagnostic standard for
peritonitis. Common bacteria isolated were Escherichia
coli, and Streptococcus species. PCT levels were measured
in serum sample in 17 studies [17-27,29-34] and in ascites
fluid sample in 5 studies [22,23,28,29,34], mostly using the
LUMI test kit (BRAHMS, Berlin, Germany) and Semi-
quantitative PCT-Q testing assays.
Quality assessment
The QUADAS tool was used for study quality assess-
ment, and Figure 2 provided an overall impression of
the quality of the included studies. Five of 18 included
studies were prospective [17,18,22,23,25], and 13 studies
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Table 1 Characteristics of included studies
Author, year,
country












TP(n) FP(n) FN(n) TN(n) PCT testing assays (FAS of PCT assays)
Cekin, 2013 [21] Retrospective 63.4 Cirrhotic 59/24 SBP Serum PCT 0.42 78%, 75% 46 6 13 18 ECLIA (0.5 ng/ml)
Turkey
Connert, 2003 [25] Prospective 57 Cirrhotic 19/81 SBP Serum PCT 0.615 94.7%, 70.4% 18 24 1 57 LUMI test (0.07 ng/ml)
Germany
Guz, 2006 [17], Prospective 46.6 PD 21*/35 PDRP Serum PCT 0.5 62%, 94% 13 2 8 33 LUMI test (0.02 ng/ml)
Turkey Serum PCT 0.75 43%, 98% 9 1 12 34
Serum PCT 1.5 38%, 99% 8 0 13 35
Serum CRP 6 95%, 67% 20 12 1 23
Lai, 2013 [27] Retrospective 58.2/55.9 Cirrhotic 45/45 SBP Serum PCT 0.5 83%, 81% 37 9 8 36 ECLIA (0.5 ng/ml)
China Serum CRP 10 75%, 63% 34 17 11 28
Lam, 2008 [18], Prospective 63.8 PD 35/165 PDRP Serum PCT 0.5 80%, 92% 28 13 7 152 LUMI test (0.06 ng/ml)
Hong Kong
Liu, 2006 [31] Retrospective 52/42 Cirrhotic 17/20 SBP Serum PCT 0.5 100%, 100% 17 0 0 20 Semi-quantitative PCT-Q (0.5 ng/ml)
China
Liu, 2012 [32] Retrospective 45.8/43.8 Cirrhotic 55/45 SBP Serum PCT 0.5 91%, 100% 50 0 5 45 Semi-quantitative PCT-Q (0.5 ng/ml)
China
Öztürk, 2010 [20] Retrospective 49.0/44.8 PD 50/50 PDRP Serum PCT 0.5 42%, 84% 21 8 29 42 Semi-quantitative PCT-Q (0.5 ng/ml)
Turkey Serum PCT 2 14%, 100% 7 0 43 50
Serum CRP 50 40%, 100% 20 0 30 50
Serum CRP 8 90%, 11.9% 45 44 5 6
Spahr, 2001 [22], Prospective 58.1/57.9 Cirrhotic 10/10 SBP Serum PCT 0.615 50%, 90% 5 1 5 9 LUMI test (0.07 ng/ml)
Switzerland Ascitic PCT 0.5 30%, 100% 3 0 7 10
Viallon, 2000 [23] Prospective 58.8/57.6 Cirrhotic 21/40 SBP Serum PCT 0.76 95%, 98% 20 1 1 39 LUMI test (0.07 ng/ml)
France Serum CRP 80 62%, 92% 13 3 8 37
Ascitic PCT 0.3 95%, 85% 20 6 1 34
Wu, 2014 [33] Retrospective 50.8/53.0 ESLD 178/184 SBP Serum PCT 0.443 84.3%, 92.7% 150 14 28 170 Immunoluminometric assay (0.1 ng/ml)
China Serum PCT 0.462 83.7%, 94.9% 149 10 29 174
Serum PCT 0.500 81.0%, 96.1% 144 7 34 177
Xie, 2014 [34] Retrospective 28-71 Cirrhotic 56/36 SBP Serum PCT 0.5 89.3%, 94.4% 50 2 6 34 ECLIA (0.5 ng/ml)
China Ascitic PCT 0.5 71.4%, 100% 40 0 16 36




















Table 1 Characteristics of included studies (Continued)
Yilmaz, 2007 [19] Retrospective 51.3/50.7 PD 20/20 PDRP Serum PCT 0.5 70%, 100% 14 0 6 20 Semi-quantitative PCT-Q (0.5 ng/ml)
Turkey Serum CRP 8 100%, 55% 20 9 0 11
Yuan, 2013 [24] Retrospective 55.9/54.8 CSHB 42/42 SBP Serum PCT 0.48 95%, 79% 40 9 2 33 Automated Immunoanalysis (0.04 ng/ml)
China Serum PCT 0.67 36%, 98% 15 1 27 41
Serum CRP 11.6 86%, 69% 36 13 6 29
Serum CRP 16.1 64%, 95% 27 2 15 40
Zhang, 2004 [29] Retrospective 51.4 Cirrhotic 41/21 SBP Serum PCT 13.7 87.8%, 100% 36 0 5 21 Immunoluminometric assay (0.1 ng/ml)
China Ascitic PCT 9.5 70.7%, 80.9% 29 4 12 17
Zhang, 2010 [30] Retrospective 58.0 Cirrhotic 34/39 SBP Serum PCT 2 79.4%, 89.7% 27 4 7 35 Semi-quantitative PCT-Q (0.5 ng/ml)
China Serum CRP 8 55.2%, 86.7% 19 5 15 34
Zhang, 2003 [26] Retrospective 48.6 Cirrhotic 38/51 SBP Serum PCT 10 84.2%, 94.1% 32 3 6 48 Semi-quantitative PCT-Q (0.5 ng/ml)
China
Note: PD peritoneal dialysis, PDRP peritoneal dialysis-related peritonitis, FAS functional assay sensitivities, PCT Procalcitonin, CRP C-reactive protein, SBP Spontaneous bacterial peritonitis, ECLIA electrochemiluminescence
immunoassay, CSHB Chronic severe hepatitis, ESLD end-stage liver disease.



















were retrospective in design [19-21,24,26-34]. All studies
had clearly defined inclusion and exclusion criteria. All
of these studies used ascitic polymorphonuclear (PMN)
cells count, however, as different definitions were used
in different trials, which might lead to potential spec-
trum bias existed.
None of included trials reported withdrawals or unin-
terpretable result. Eleven studies did not state whether
the PCT results were interpreted without knowledge of
outcome assessment [17,18,21,24,28-34], it was poorly
reported whether the reference standard results were
interpreted blindly, and in only one study, the resear-
chers were blinded to the index test while verifying re-
sults by reference standard [23]. These issues might lead
to overstated measures of diagnostic accuracy, which is
known as a review bias.
Data extraction and calculation
We calculated the numbers of true-positive, false-positive,
false-negative and true-negative based on the provided in-
dexes of sensitivity, specificity, and sample size values.
PCT measurement was performed at the beginning of the
trial in most of the included studies. We reported the
PCT and C-reactive protein (CRP) cut-off values in
Table 1. Cut-off values for serum or ascitic PCT var-
ied between studies, ranging from 0.42-13.7 ng/ml, or
0.3-10 ng/ml, respectively.
Diagnostic accuracy indices
A total of seventeen studies [17-27,29-34] have investi-
gated the diagnostic value of PCT in serum. Our analysis
indicated that serum PCT has a high degree of accuracy
for the diagnosis of peritonitis. Pooled sensitivity and
specificity estimates of PCT were 0.83 (95% CI: 0.76-
0.89), 0.92 (95% CI: 0.87-0.96), respectively (Figures 3
and 4). We also constructed summary ROCs for both
PCT and CRP, the results showed that AUROC of PCT
was 0.94 (95% CI: 0.92-0.96) (Figure 5). The high po-
sitive likelihood ratio (LR+: 11.06; 95% CI: 6.31–19.38)
indicates that the PCT test is suitable for a rule-in diag-
nosis, but its poor negative likelihood ratio (LR−: 0.18,
95% CI: 0.12–0.27) makes it less useful as a rule-out tool.
As shown in Table 2, seven studies reported diagnostic
value of serum CRP levels [17,19,20,23,24,27,30]. The
pooled sensitivity for CRP was 0.76 (95% CI: 0.58–0.88),
lower than PCT, the specificity was 0.81 (95% CI: 0.63–
0.92), lower than PCT, and the AUROC was 0.85 (95% CI:
0.82-0.88) (Figure 6). CRP has a poorer LR + (4.01, 95%
CI: 2.16–7.45) and LR − (0.29, 95% CI: 0.17–0.49). Overall,
PCT has a higher discriminative capability than CRP in
diagnosing peritonitis. The diagnostic OR for PCT was
61.52 (95% CI: 27.58-137.21), while the diagnostic OR for
CRP was 13.54 (95% CI: 7.25-25.28). There was substantial
degree of heterogeneity for PCT (I2 = 90.08, 95% CI:
80.35-99.81) and CRP (I2 = 96.81, 95% CI: 94.54-99.09).
There were only 5 studies [22,23,28,29,34] reporting
accuracy parameters on ascitic PCT, across all settings.
We found that a diagnostic OR was 80.93 (95% CI:
15.26-429.28) for ascitic PCT level to predict peritonitis
at sensitivity and specificity of 0.79 (95% CI: 0.54-0.92)
and 0.96 (95% CI: 0.81-0.99) respectively. The pooled
positive likelihood ratio was 17.85 (95% CI: 4.11-77.59),
negative likelihood ratio was 0.22 (95% CI: 0.09-0.54),
and the AUROC was 0.96 (95% CI, 0.94-0.97). The I2
Figure 2 QUADAS (Quality Assessment of Diagnostic Accuracy Studies) criteria for included studies.
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Figure 3 Forest plot of the pooled sensitivity of serum PCT level in predicting bacterial peritonitis across all settings.
Figure 4 Forest plot of the pooled specificity of serum PCT level in predicting bacterial peritonitis across all settings.
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statistic was 77.94%, indicating significant heterogeneity
across these studies (Table 2).
Subgroup analysis
Subgroup analyses were performed to explore the source
of heterogeneity. Nine studies [17-20,27,31-34] reported
test results with the use of a common PCT cutoff value
(0.5 ng/mL). The pooled sensitivity and specificity were
0.81 (95% CI: 0.68–0.89) and 0.95 (95% CI: 0.89–0.98)
respectively. Three studies [21,24,33] also reported diag-
nostic accuracy parameters using a lower serum PCT
cut-off value (0.42-0.48 ng/mL), sensitivity increased ap-
preciably (0.85, 95% CI: 0.80–0.88) and the specificity
decreased correspondingly (0.89, 95% CI: 0.79–0.94). In
contrast, subgroup analysis on parameters using higher
cut-off values (0.615–13.7 ng/mL) showed slightly de-
creased sensitivity, but increased specificity, compared
with the overall estimates [17,20,22-26,29,30].
There were four studies [17-20] carried out on peri-
toneal dialysis (PD) patients, as shown in Table 2, The
value of serum PCT level to predict peritonitis in PD pa-
tients (DOR: 18.33; AUROC: 0.89) was substantially lower
compared with that in all included patients (DOR: 61.52;
AUROC: 0.94). Eleven studies [21-23,25-27,29-32,34] had
reported accuracy parameters on serum PCT in cirrhotic
patients. The pooled sensitivity and specificity were 0.86
and 0.94 respectively, and the AUROC was 0.91 (95% CI:
0.89-0.94), indicating that serum PCT also had acceptable
predictive performance in cirrhotic patients. The sub-
group analyses stratified by the different patient popula-
tions (PD and Cirrhotic) using common PCT cut-offs
(0.5 ng/ml) showed that the diagnostic value among PD
patients (DOR: 18.33; AUROC: 0.89) was substantially lo-
wer compared with that in cirrhotic patients (DOR: 245.08;
AUROC: 0.94) (shown in Table 2).
As all these included studies using different PCT assays
with widely varying functional assay sensitivities (FAS)
(shown in Table 1), we have performed the subgroup ana-
lyses based on different FAS of the PCT assays, but the re-
sult showed that there was no significant difference on the
diagnostic value of PCT among trials of different PCT as-
says (DOR: 65.43; AUROC: 0.95 vs DOR: 71.41; AUROC:
0.95; shown in Table 2). While the subgroup analysis
restricted to 8 studies [17,18,22-25,29,33] using the higher
sensitive test tool for PCT (FAS ≤ 0.1 ng/ml) showed
the sensitivity increased, but the specificity decreased
slightly.
We also performed the subgroup analyses based on
different dominated language, and the result showed that
the value of serum PCT to diagnosis peritonitis in eight
trials published in Chinese (DOR: 141.09; AUROC: 0.93)
[26,27,29-34] was substantially higher compared with
that published in English (DOR: 29.16; AUROC: 0.92;
shown in Table 2) [17-25].
Figure 5 Hierarchical summary receiver operating characteristic plot of serum PCT level to predict bacterial peritonitis across all
settings. The curve is represented by the straight line, each of the analyzed studies is represented by a fork. The point estimate to which
summary sensitivity and specificity correspond is represented by the diamond shape, and the respective 95% confidence intervals are
represented by the dashed line. Abbreviation: AUC, area under the curve; SENS: summary sensitivity; SPEC: summary specificity. SROC: summary
receiver operating characteristic.
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I2 (95% CI) Likelihood ratio (95% CI) Publication bias
(Deek’s test P)Positive Negative
Serum PCT
Overall analysis 17 1644 0.83(0.76-0.89) 0.92(0.87-0.96) 61.52(27.58-137.21) 0.94(0.92-0.96) 90.08(80.35-99.81) 11.06(6.31-19.38) 0.18(0.12-0.27) 0.973
PD patients 4 391 0.64(0.47-0.78) 0.91(0.85-0.94) 18.33(6.32-53.12) 0.89(0.87-0.92) 0.00(0.00-100.00) 7.19(3.75-13.82) 0.39(0.24-0.62) 0.629
Cirrhotic patients 11 807 0.86(0.81-0.89) 0.94(0.85-0.97) 85.89(27.31-270.19) 0.91(0.89-0.94) 80.65(58.51-100.00) 13.17(5.27-32.86) 0.15(0.11-0.21) 0.734
High cut-off PCT valuea 9 640 0.68(0.44-0.85) 0.97(0.91-0.99) 60.01(24.19-148.85) 0.95(0.93-0.97) 97.33(95.53-99.13) 20.02(8.29-48.37) 0.33(0.17-0.64) 0.813
Low cut-off PCT valueb 3 529 0.85(0.80-0.88) 0.89(0.79-0.94) 42.57(19.72-91.89) 0.86(0.83-0.89) 61.42(13.01-100.00) 7.42(3.89-14.17) 0.17(0.13-0.23) 0.299
Common PCT cut-off valuec 9 1072 0.81(0.68-0.89) 0.95(0.89-0.98) 75.32(21.13-268.52) 0.95(0.93-0.97) 15.30(0.00-100.00) 15.35(6.67-35.28) 0.20(0.12-0.35) 0.973
Common PCT cut-off in PD 4 391 0.64(0.47-0.78) 0.91(0.85-0.94) 18.33(6.32-53.12) 0.89(0.87-0.92) 0.00(0.00-100.00) 7.19(3.75-13.82) 0.39(0.24-0.62) 0.629
Common PCT cut-off in SBP 5 681 0.87(0.78-0.92) 0.97(0.85-0.99) 245.08(26.73-2247.33) 0.94(0.92-0.96) 60.35(10.58-100.00) 33.02(5.06-215.47) 0.13(0.07-0.23) 0.562
Publication in Chinese 8 905 0.86(0.81-0.89) 0.95(0.89-0.98) 141.09(42.44-469.04) 0.93(0.90-0.95) 30.79(0.00-100.00) 20.12(7.64-52.94) 0.14(0.10-0.19) 0.493
Publication in English 9 739 0.79(0.63-0.89) 0.89(0.81-0.94) 29.16(11.78-72.17) 0.92(0.89-0.94) 91.95(84.48-99.43) 6.99(3.97-12.28) 0.24(0.13-0.44) 0.683
FAS > 0.1 ng/ml 9 704 0.82(0.71-0.90) 0.93(0.85-0.97) 65.43(17.30-247.48) 0.95(0.92-0.96) 48.24(0.00-100.00) 12.26(5.01-29.99) 0.18(0.10-0.33) 0.508
FAS≤ 0.1 ng/ml 8 940 0.86(0.76-0.92) 0.92(0.85-0.96) 71.41(43.93-116.09) 0.95(0.93-0.97) 89.60(79.27-99.92) 10.76(6.01-19.26) 0.15(0.08-0.26) 0.786
Ascitic PCT
Overall analysis 5 418 0.79(0.54-0.92) 0.96(0.81-0.99) 80.93(15.26-429.28) 0.96(0.94-0.97) 77.94(52.08-100.00) 17.85(4.11-77.59) 0.22(0.09-0.54) 0.075
Serum CRP
Overall analysis 7 499 0.76(0.58-0.88) 0.81(0.63-0.92) 13.54(7.25-25.28) 0.85(0.82-0.88) 96.81(94.54-99.09) 4.01(2.16-7.45) 0.29(0.17-0.49) 0.676
Note: PCT procalcitonin, PD peritoneal dialysis, CRP C-reactive protein, SBP Spontaneous bacterial peritonitis, FAS functional assay sensitivities, AUROC area under the receiver operating characteristic curve.



















PCT and long-term adverse outcomes of peritonitis
Only two studies reported the relationship between long-
term survival outcome and the PCT level. Lam et al. [18]
found that there was no difference in the survival rate be-
tween PD patients with PCT >0.38 ng/mL and patients
with PCT <0.38 ng/mL (p = 0.37). However, Connert et al.
[25] reported that cirrhotic patients with PCT levels above
0.58 ng/ml were associated with poor survival compared
to those with levels below 0.58 ng/ml, and significant dif-
ferences were found in mean PCT level between pa-
tients who died or survivied during the follow-up period
(p < 0.01).
Publication bias
We used funnel plots to assess the publication bias, as
shown in Table 2, there was no significant evidence of
potential publication bias was noted by Deek’s test.
Discussion
PCT is a polypeptide of 116 amino acids (molecular
weight 13 kDa) with a long half-life of 25-30 h [5]. It
was first identified during studies of hypocalcaemia asso-
ciated with Staphylococcal toxic shock syndrome [35],
and then in 1993, its elevated level was found in patients
with bacterial infection. It is most commonly produced
from neuroendocrine cells in non-thyroidal tissues such
as lung, liver or kidney during inflammation [36,37].
Unlike other inflammatory markers (e.g., CRP), PCT
level does not respond to viral infection or sterile in-
flammation. In the serum of healthy individuals, PCT
is undetectable (<0.01 ng/ml) and a value of >0.5 ng/ml
is considered abnormal [5,36]. Many studies have shown
that PCT could rapidly increase in response to bacterial
inflammatory stimuli, and it could be recommended as
an effective biomarker in the detection and differential
diagnosis of inflammatory states [4,6,38,39]. However,
there are few meta-analyses on the accurancy of PCT in
predicting bacterial peritonitis. In our analysis, which
included 1827 patients, we showed that the measure-
ment of serum PCT could provide considerable predictive
value (DOR: 61.52; AUROC: 0.94) for the diagnosis of bac-
terial peritonitis, and that this predictive capacity is better
than that provided by CRP (DOR: 13.54; AUROC: 0.85).
There are many types of bacterial peritonitis. In cli-
nical practice, PD related peritonitis and spontaneous
bacterial peritonitis (SBP) in cirrhotic patients are most
common types in clinical practice. PD represents an im-
portant method for the management of uremic patients.
Despite a decreasing incidence of PD-related infectious
complications over the last couple of decades, peritonitis
remains a leading complication and a common cause of
infection-related mortality in PD patients [40,41]. Mi-
crobiological culture systerm in PD effluent is the gold
standard for diagnosis of PD-associated peritonitis, but
suffers from high false negative rates and delayed report-
ing [40]. In this regard, the use of some new reliable
diagnostic markers such as PCT can greatly improve the
turnaround time of laboratory reports. It has been dem-
onstrated that renal elimination is the major pathway for
clearance of PCT [42], and a previous study performed
Figure 6 Hierarchical summary receiver operating characteristic plot of serum CRP level to predict bacterial peritonitis across all
settings. Abbreviation: AUC, area under the curve; SENS: summary sensitivity; SPEC: summary specificity. SROC: summary receiver
operating characteristic.
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by Opatrna et al. [43] showed that the serum levels of
PCT were increased in PD patients without overt signs
of infection compared with healthy volunteers. But
follow-up studies revealed the plasma clearance rate
of PCT correlated weakly with renal function dysfunc-
tion, and it might not influence clinical decisions based on
PCT [42,44]. Our meta-analysis also confirmed an ac-
ceptable diagnostic accuracy for PCT testing in PD pa-
tients (Sensitivity, 0.64; Specificity, 0.91; DOR: 18.33;
AUROC: 0.89).
SBP is the most frequent and life-threatening infection
in decompensated cirrhotic patients [45]. Owing to an
inadequately immune response, clinical manifestations
of SBP in cirrhotic patients may be atypical. There is
considerable evidence indicating that high PCT levels
may be related to infections in cirrhosis [25]. Although
the liver is considered as the main source of PCT, a
study performed by Bota et al. [46] showed that serum
levels of PCT did not significantly decrease in cirrhotic
patients. Moreover, PCT had similar predictive power
for infection in patients with and without cirrhosis. In
accordance with these findings, our meta-analysis also
showed that serum PCT testing has a good accuracy
for the diagnosis of bacterial peritonitis in cirrhotic
patients (Sensitivity, 0.86; Specificity, 0.94; DOR: 85.89;
AUROC: 0.91).
Some authors postulated that ascitic PCT might be
more sensitive than serum PCT for the early identifica-
tion of peritonitis, because bacterial infection could trig-
ger peritoneal inflammatory cells to produce PCT, which
then may accumulate in the ascitic fluid. In the present
study, the pooled analysis of 5 studies [22,23,28,29,34]
suggested that ascitic PCT (DOR: 80.93; AUROC: 0.96)
to was similar with serum PCT (DOR: 85.89; AUROC:
0.91) in diagnosing peritonitis in cirrhotic patients. And
Viallon et al. found that PCT detection in ascitic fluid
was due to hyperpermeability of peritoneum, while PCT
was not synthesized by leucocytes in ascites [23]. These
small and in part not significant differences rather
supported the assumption of Viallon et al. that PCT
detection in the ascitic fluid was the result of a pas-
sive shift due to increased vascular permeability in-
stead of an intraperitoneal synthesis. Considering the
serious harm for the missed diagnoses of peritonitis,
it is not recommended to use ascitic PCT testing as
a stand-alone test, and more larger prospective trials
are needed to fully elucidate the potential diagnostic
value of ascitic PCT.
Fungal peritonitis is a quite uncommon but potentially
fatal complication both in peritoneal dialysed [47] and
advanced liver cirrhosis patients [48]. The clinical char-
acteristics of fungal peritonitis is not typical and easy to
be misdiagnosed. In addition, fungi infections usually re-
sult in treatment failure with antibacterial agents and
even removing the PD catheter. Early recognition of fun-
gal peritonitis allows for timely and effective therapy
with improved outcome, but it is hampered by a lack of
a reliable diagnostic tool. There is a significant body of
clinical research indicates good diagnostic accuracy for
the PCT test for discrimination between invasive fungal
infection and bacterial infection [6,49]. However, the dif-
ferential diagnostic value of the PCT testing on fungal
peritonitis has not been explored. It is speculated that
the PCT testing can provide effective sensitivity and spe-
cificity for distinguishing fungal peritonitis from bacter-
ial peritonitis.
The pooled likelihood ratio estimates (LR+ and LR−)
was analyzed to calculate post-test probabilities. In a vir-
tual population with a 20% prevalence of peritonitis (the
actual prevalence of SBP in hospitalized cirrhotic pa-
tients with ascites was 10-30% [50]), use of a serum PCT
test with an LR + of 11.06 would increase the posttest
probability (positive predictive value) to 72%. In other
words, about 3 in 4 patients with positive PCT test re-
sults may have confirmed peritonitis. Likewise, in the
same population, application of a serum PCT test with a
negative likelihood ratio of 0.18 would reduce the post-
test probability to 5%, In other words, 1 in 20 patients
with negative PCT results may have peritonitis. Using
data from the subgroup with a higher PCT cut-off value
(0.615–13.7 ng/mL), a similar calculation indicated a
positive post-test probability of 85% and a negative
post-test probability of 7%.
There was substantial heterogeneity detected for the
overall results between the eighteen included studies.
Potential source of heterogeneity included the different
characteristics of the studies, such as methodological qua-
lity, admission category, size of the study populations,
different reference standards in PD or cirrhotic patients
for peritonitis (ascitic PMN > 50/mm3 or > 250/mm3, re-
spectively), different countries and different human race
and different methods used for measurement of PCT
(LUMItest, ECLIA and the Semi-quantitative PCT-Q as-
say systems). And other unrecorded differences among
these studies might also contribute to the heterogeneity.
Evaluation with individual patient data or meta-regression
would help in this analysis of the sources of heterogeneity.
However, the meta-regression would have to adjust for
factors at individual patient level, which were not available
at present, therefore it limited our ability to further evalu-
ate heterogeneity. On the other hand, using more homo-
geneous trials could solve this difficulty, but it could
induce selection bias.
There are several potential limitations to our study
that should be addressed.
First, in our meta-analysis, various PCT testing assay
tools and various PCT cut-off values were used in differ-
ent included studies, and sensitivities and specificities
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varied between studies. We performed subgroup ana-
lysis and constructed the HSROC curve and calculated
AUROC to diminish the influence of different PCT assays
and cut-off values effect. Despite the adjustment by bivari-
ate model, there might be residual influence on the accur-
acy of pooled diagnostic parameters. Second, most of the
studies have a case–control design, it has been demon-
strated that the case–control design could over-estimate
the accuracy of a diagnostic test [51], therefore more lar-
ger prospective trials should be performed to elucidate the
diagnostic value of PCT. Third, as mentioned before, our
study suffered from moderate heterogeneity, mainly owing
to different patients characteristics, and different defini-
tions of peritonitis. Fourth, despite no significant publi-
cation bias was detected, however, this study included
9 low-quality Chinese language trials, which might
lead to an overestimation of overall diagnostic accur-
acy of PCT, especially because positive studies were
more easily reported.
Conclusion
In conclusion, our meta-analysis shows that PCT is a
helpful marker in identifying bacterial peritonitis, Al-
though PCT performs as well in PD patients as in cirrho-
tic or severe hepatitis patients, use of a common cut-off
value may further enhance accuracy. Compared with CRP,
PCT is superior in the diagnosis of bacterial peritonitis.
However, it is important to note that PCT cannot be rec-
ommended as a “gold standard” test for peritonitis up to
now, and should be interpreted in combination with other
clinical, analytical, and/or microbiological data. Given the
limits of PCT as a single marker, additional large prospec-
tive studies should determine its diagnostic value in bac-
terial peritonitis, when interpreted in association with
other biomarkers.
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